PVLA files NDA for QTORIN microLM; FDA approval expected in 2027
PVLA advanced its QTORIN platform for rare skin and vascular diseases, filing a lead NDA for microLM and anticipating FDA approval in 2027. The company cites strong IP, regulatory exclusivity and clinical data.
The company said it is advancing its QTORIN platform for rare skin and vascular diseases, with a lead NDA filed for microLM and FDA approval anticipated in 2027. It said strong IP, regulatory exclusivity and robust clinical data support high pricing and market adoption, while additional indications are progressing.